# A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

> **NCT04844775** · PHASE1 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 68 (actual)

## Conditions studied

- Healthy Adults

## Interventions

- **BIOLOGICAL:** Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L
- **BIOLOGICAL:** DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)
- **BIOLOGICAL:** DNA-HIV-PT123 4mg and CN54gp140/MPLA-L

## Key facts

- **NCT ID:** NCT04844775
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-05
- **Primary completion:** 2024-09-09
- **Final completion:** 2024-09-09
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-07-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04844775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04844775, "A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04844775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*